Pat

J-GLOBAL ID：200903060560666495

自己免疫疾患治療のための乳酸菌の使用

Inventor： アレンフォール ジャン ,  ベルゲン アンナ ,  ラスク キャロル ,  ウォルド アグネス ,  アガイベイク-ラバサーニ シャハラン
Applicant, Patent owner： プロビ エービー
Agent (4)： 三枝 英二 ,  斎藤 健治 ,  中野 睦子 ,  林 雅仁
Gazette classification：公表公報
Application number (International application number)：2008534491
Publication number (International publication number)：2009511471
Application date： Oct. 06, 2006
Publication date： Mar. 19, 2009
Summary：

本発明は、自己免疫疾患の治療及び/又は予防のための医薬の製造のための、乳酸菌から選択される少なくとも一種のプロバイオティクス細菌(Probiotic bacteria)株の使用に関する。【選択図】なし

Claim (excerpt)：

自己免疫疾患の治療及び/又は予防のための薬学的組成物の製造のための、乳酸菌から選択された、少なくとも1種のプロバイオティクス細菌 (Probiotic bacteria) 株の使用。

IPC (8)：

A61K 35/74 ,  A61P 37/02 ,  A61P 37/08 ,  A61P 11/06 ,  A61P 29/00 ,  A61P 1/00 ,  A61P 3/10 ,  C12N 1/20

FI (8)：

A61K35/74 A ,  A61P37/02 ,  A61P37/08 ,  A61P11/06 ,  A61P29/00 101 ,  A61P1/00 ,  A61P3/10 ,  C12N1/20 E

F-Term (19)：

4B065AA30X ,  4B065BA21 ,  4B065CA44 ,  4C087AA01 ,  4C087AA02 ,  4C087BC56 ,  4C087CA09 ,  4C087NA14 ,  4C087ZA02 ,  4C087ZA66 ,  4C087ZA68 ,  4C087ZA89 ,  4C087ZB05 ,  4C087ZB07 ,  4C087ZB08 ,  4C087ZB11 ,  4C087ZB13 ,  4C087ZB15 ,  4C087ZC35

Patent cited by the Patent：

Cited by applicant (2)

• Lactobacillusparacaseiの新規株
  Gazette classification：公表公報   Application number：特願2002-524045   Applicant：プロビエービー
• IgE抗体産生抑制剤および抗アレルギー剤
  Gazette classification：公開公報   Application number：特願平7-172949   Applicant：株式会社ヤクルト本社

Cited by examiner (2)

• Lactobacillusparacaseiの新規株
  Gazette classification：公表公報   Application number：特願2002-524045   Applicant：プロビエービー
• IgE抗体産生抑制剤および抗アレルギー剤
  Gazette classification：公開公報   Application number：特願平7-172949   Applicant：株式会社ヤクルト本社

Article cited by the Patent：

Cited by applicant (8)

• Modulation of the Effect of Dextran Sulfate Sodium-Induced Acute Colitis by the Administration of Di
• Induction by a lactic acid bacterium of a population of CD4+ T cells with low proliferative capacity
• Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice
• The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sc
• Treatment of Psoriasis with Interleukin-10
• Recombinant Human IL-10 Prevents the Onset of Diabetes in the Nonobese Diabetic Mouse
• Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed h
• Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-1

Cited by examiner (18)

• Modulation of the Effect of Dextran Sulfate Sodium-Induced Acute Colitis by the Administration of Di
• Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed h
• Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-1
• Induction by a lactic acid bacterium of a population of CD4+ T cells with low proliferative capacity
• Modulation of the Effect of Dextran Sulfate Sodium-Induced Acute Colitis by the Administration of Di
• Induction by a lactic acid bacterium of a population of CD4+ T cells with low proliferative capacity
• Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice
• The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sc
• Treatment of Psoriasis with Interleukin-10
• Recombinant Human IL-10 Prevents the Onset of Diabetes in the Nonobese Diabetic Mouse
• Modulation of the Effect of Dextran Sulfate Sodium-Induced Acute Colitis by the Administration of Di
• Induction by a lactic acid bacterium of a population of CD4+ T cells with low proliferative capacity
• Protective effect of transforming growth factor beta 1 on experimental autoimmune diseases in mice
• The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sc
• Treatment of Psoriasis with Interleukin-10
• Recombinant Human IL-10 Prevents the Onset of Diabetes in the Nonobese Diabetic Mouse
• Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed h
• Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-1